The Lynx Group

Susanne Liewer, PharmD, BCOP


Authored Items

Toxicity of Bendamustine Therapy

May 2013, Vol 4 No 3 - Uncategorized

Bendamustine is an active chemotherapy agent approved by the FDA for the treatment of patients with chronic lymphocytic leukemia (CLL) and for specific populations of patients with non-Hodgkin lymphoma (NHL). While bendamustine has been reported to be very effective in treating these malignancies, its tolerable toxicity profile has made it [ Read More ]

Stakeholder’s Perspective: Pharmacy Considerations

December 2012, Vol 4 No 1 - Uncategorized

Since the approval of bendamustine, healthcare practitioners have additional treatment options available to patients with specific hematologic malignancies. In the United States, bendamustine was approved for patients with chronic lymphocytic leukemia (CLL) or indolent B-cell non-Hodgkin lymphoma (NHL) who had progressed within 6 months of receiving rituximab-containing regimens. In Europe, [ Read More ]

Sign me up!